Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials

Published:2024-06 Issue:6 Volume:24 Page:650-664
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Li Xiaojiao,Liu Yusi,Wang Meng,Gao Lei,Liu Jingrui,Zhang Hong,Wu Min,Chen Hong,Lou Jinfeng,Wang Jing,Chen Jing,Geng Guozhu,Ma Zhenkun,Ding Yanhua

Funder

National Natural Science Foundation of China

Jilin University

TenNor Therapeutics

Natural Science Foundation of Jilin Province

Publisher

Elsevier BV

Reference26 articles.

1. Helicobacter pylori World Gastroenterology Organization global guideline;Katelaris;J Clin Gastroenterol,2023

2. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis;Hooi;Gastroenterology,2017

3. ACG clinical guideline: treatment of Helicobacter pylori infection;Chey;Am J Gastroenterol,2017

4. 2021 Guidelines on Helicobacter pylori. Coincidences and divergences between the Spanish and World Gastroenterology Organisation (WGO) guidelines;Fernández Salazar;Rev Esp Enferm Dig,2022

5. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report;Malfertheiner;Gut,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel dual targeted antibacterial agent for Helicobacter pylori;The Lancet Infectious Diseases;2024-06

2. 40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention;The Lancet;2024-06